CEO of Celgene
Celgene has entered into a 10-year collaboration with the cellular immunotherapy company Juno Therapeutics, which includes an initial billion payment, according to a joint statement released by the companies.
Celgene has a number of already approved therapies for patients with hematologic malignancies and other types of cancer, including pomalidomide, lenalidomide, azacitidine, romidepsin, and nab-paclitaxel. Additionally, the company has a broad research pipeline.
... to read the full story